APA (7th ed.) Citation

AC, C., AP, K., JU, B., JK, R., KM, A., X, G., . . . PA, N. (2025). Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer's disease: A single ascending-dose study in healthy participants. Alzheimer's research & therapy, 17(1), 144. https://doi.org/10.1186/s13195-025-01798-4

Chicago Style (17th ed.) Citation

AC, Conley, et al. "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M1 Positive Allosteric Modulator VU0467319 for Alzheimer's Disease: A Single Ascending-dose Study in Healthy Participants." Alzheimer's Research & Therapy 17, no. 1 (2025): 144. https://doi.org/10.1186/s13195-025-01798-4.

MLA (9th ed.) Citation

AC, Conley, et al. "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M1 Positive Allosteric Modulator VU0467319 for Alzheimer's Disease: A Single Ascending-dose Study in Healthy Participants." Alzheimer's Research & Therapy, vol. 17, no. 1, 2025, p. 144, https://doi.org/10.1186/s13195-025-01798-4.